Suggestions
Marie-Eve Beaulieu
Co-founder and Chief Scientific Officer at Peptomyc
Marie-Eve Beaulieu is a prominent figure in the biotechnology industry, serving as the Co-founder, Chief Scientific Officer, and Board member at Peptomyc.23 Her background is rooted in scientific research, particularly in the field of pharmacology.
Education and Research
Dr. Beaulieu holds a PhD in Pharmacology from the Université de Sherbrooke, which she completed in 2011.1 During her doctoral studies, she worked under the supervision of Dr. Pierre Lavigne, focusing on the structural biology of c-Myc and Max proteins.1 This research likely laid the foundation for her future work in targeted cancer therapies.
Professional Career
At Peptomyc, Marie-Eve Beaulieu plays a crucial role in driving the company's scientific direction and strategy. As the Chief Scientific Officer, she is responsible for overseeing the research and development efforts of the company.2 Her position as a co-founder and board member also suggests that she has been instrumental in shaping the company's vision and growth from its inception.3
Expertise and Contributions
Dr. Beaulieu's expertise extends beyond her scientific knowledge. She is recognized as:
- A Senior Business Developer
- An Innovation Leader
- An Investment Pitch Expert
- A Status Quo Challenger4
These roles highlight her ability to bridge the gap between scientific research and business development, which is crucial for a biotechnology startup.
Advocacy and Leadership
Marie-Eve Beaulieu is also actively involved in promoting women in science and supporting gender equality in the field.24 Her participation in events like the International Day of Women and Girls in Science demonstrates her commitment to inspiring and empowering future generations of female scientists.
Through her work at Peptomyc and her various roles, Marie-Eve Beaulieu continues to make significant contributions to the field of cancer research and biotechnology, while also advocating for important causes within the scientific community.
Highlights
Patients are at the heart of Peptomyc’s journey.
In our fight against cancer, we are driven by the dedication and expertise of professionals pushing the boundaries of medical research. We at Peptomyc are privileged to collaborate with the best minds in the field.
Last week, our team leveraged the #EUeic #USsoftlanding program to learn from leaders at INSEAD, Gilead Sciences, Horizon, Stanford University School of Medicine, Gladstone Institutes and the innovative life sciences community of Silicon Valley. We also got closer to 14 European fellow healthtech companies selected to participate in this program, sharing reflexions and strategic thinking on how to overcome the challenges along the way to deliver our innovative solutions to the patients.
This boost in our "marathoning journey" came thanks to the support from the European Innovation Council and SMEs Executive Agency (EISMEA) and the phenomenal and inspiring Jillian Manus. 🙏
These collaborations propel us in our mission to defeat cancer with our foundational anti-MYC mini-proteins. And this is just the beginning.
#HealthcareInnovation #CancerResearch #AntiMYCProteins #Peptomyc #HealthcareForAll #InnovationInHealth Claartje Ypma Reender Beks Carolina Aguilar Nuria PastorUnai Sanchez Luque Joshua Forgy Karin Rosen MD PhDCathy O. Floris van Tol Agnès Dimey Csaba Jeney Chris Murphy Hugo Ramos jean-charles sanchez Justinas Balčiūnas Bruno Santos Simas Tatoris Joydeep Ganguly Krithika Kumar Sebastien Marque, PhD, CStat Jörg Klumbis Vall d'Hebron Institute of Oncology (VHIO)
This week, I'm presenting Peptomyc, our company developing MYC-targeting mini-proteins for cancer treatment, at the #EICSoftLanding program, together with Jörg Klumbis. I feel truly grateful for this fantastic learning opportunity, and proud to see Peptomyc selected to represent European innovation in the US! #Eueic
